DCTHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DELCATH SYSTEMS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.37+0.29 (+2.06%)
Close on Oct 19, 2026
- Market cap
- $571.37M
- P/E (TTM)
- 1437.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
86.2%
Operating margin
0.8%
Net margin
3.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +129.1% | +215.3% | – | +47.5% | |
| Gross profit | +136.8% | +230.6% | +135.9% | +49.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -505.4% | -307.3% | 3.0% | |
| Return on assets | -70.5% | -98.9% | 2.7% | |
| Current ratio | 0.95 | 3.22 | 10.92 | |
| Interest coverage | -1.1× | – | – | |
| Inventory turnover | 0.8× | – | 1.4× | |
| Capex to revenue | 13.0% | – | 1.8% | |
| Diluted shares | 0M | 3M | 40M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Delcath Systems generated $120.00M from operations and spent $8.52M on capital expenditure, dividends and share buybacks. 30% of that went back into the business.
Generated
$120.00M
Used
$8.52M
Capital expenditure$2.52M30%Dividends$00%Share buybacks$6.00M70%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3.2%
×Asset turnover0.85×
×Equity multiplier1.11×
=Return on equity, FY20253.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3.2% | 0.85× | 1.11× | 3.0% |
| FY2024 | -70.9% | 0.65× | 1.36× | -62.4% |
| FY2023 | -2308.9% | 0.07× | 5.69× | -961.4% |
| FY2022 | -1342.7% | 0.11× | 8.37× | -1198.4% |
| FY2021 | -721.5% | 0.10× | 1.99× | -150.7% |
| FY2017 | -1661.8% | 0.12× | -54.34× | 11112.6% |
| FY2016 | -902.2% | 0.08× | 7.17× | -505.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$2.70M
- Cash generatingOperating cash flow above zero$22.52M
- Return on assets improvedROA up on the prior year-68.3% → 3.5%
- Earnings backed by cashOperating cash flow above net income$22.52M vs $2.70M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose12.01 → 10.92
- No dilutionShare count did not rise29M → 40M
- Gross margin improvedGross margin up on the prior year83.37% → 86.16%
- More efficientAsset turnover rose0.96 → 1.11